How We're Keeping You Safe | What Patients & Families Need to Know
This phase II trial studies the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed ...More
To learn more about available clinical trials related to solid tumors, contact us at cancer@cchmc.org or 513-636-2799.